Trial Profile
Phase 1/2a, Double-blind, Placebo-controlled Study with an Open-label Extension of Ropinirole Hydrochloride Extended-Release Tablets -Explorative Assessment of the Safety, Tolerability, and Efficacy after Oral Treatment in Patients with Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Apr 2021
Price :
$35
*
At a glance
- Drugs Ropinirole (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Acronyms ROPALS; ROPALS
- 22 Apr 2021 Trial design presented at the 73rd Annual Meeting of the American Academy of Neurology.
- 22 Apr 2021 Status changed from active, no longer recruiting to completed.
- 13 Sep 2019 Status changed from suspended to active, no longer recruiting.